UCB announces approval of Bimzelx
The therapy is used to treat patients with psoriatic arthritis and axial spondyloarthritis
Read More
Tag: UCB
UCB announces EMA bimekizumab verdict
In two studies the therapy demonstrated improvements when compared with the placebo
Read More
Ariceum and UCB link up to take on immune-related diseases
The companies will use proprietary technology to enable the discovery of peptide-radioisotope conjugates
Read More
Positive CHMP opinion for UCB’s bimekizumab
Therapy concerns the treatment of adults with axial spondyloarthritis and psoriatic arthritis
Read More
Cancer Research UK reach agreement with UCB
The partnership will concentrate on the development of two investigational antibodies
Read More
Pheno and UCB reveal neurodegenerative disease programme agreement
Global preclinical programme has the potential for disease modifying therapeutics
Read More
UCB reveals new Bimzelx ‘complete skin clearance’ data
Positive data represents a boost for patients with moderate to severe plaque psoriasis
Read More
NICE recommends UCB’s Fintepla for Dravet syndrome
The drug is used to treat seizures caused by this rare syndrome that is a form of epilepsy
Read More
MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway
The MHRA decision closely follows a recent positive recommendation from NICE
Read More
Interim trial data for UCB’s bimekizumab shows positive results
High levels of skin clearance achieved for moderate to severe plaque psoriasis patients
Read More
UCB’s bimekizumab data in plaque psoriasis published in The Lancet
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Read More
UCB acquires gene therapy specialist Handl Therapeutics
Company also announces new collaboration with Lacerta Therapeutics
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
